NumFin

Jiangsu Sihuan Bioengineering Co., Ltd

Sümbol: 000518.SZ

SHZ

2.29

CNY

Turuhind täna

  • -39.5269

    P/E suhe

  • -12.2204

    PEG suhe

  • 2.36B

    MRK Cap

  • 0.00%

    DIV tootlus

Jiangsu Sihuan Bioengineering Co., Ltd (000518-SZ) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete Jiangsu Sihuan Bioengineering Co., Ltd (000518.SZ) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 238.061 M, mis on 16.254 % gowth. Kogu perioodi keskmine brutokasum on 111.118 M, mis on 12.909 %. Keskmine brutokasumi suhtarv on 0.401 %. Ettevõtte eelmise aasta tulemuse puhaskasv on 0.392 %, mis on võrdne -1.504 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes Jiangsu Sihuan Bioengineering Co., Ltd fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus -0.077. Käibevara valdkonnas on 000518.SZ aruandlusvaluutas 564.82. Märkimisväärne osa neist varadest, täpsemalt 28.341, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust -0.261%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 0.379, kui neid on, aruandlusvaluutas. See näitab erinevust -25.670% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 28.366 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on -0.046%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 557.241 aruandlusvaluutas. Selle aspekti aastane muutus on -0.081%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 124.269, varude hind on 408.76 ja firmaväärtus 0, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 46.65. Kontovõlad ja lühiajalised võlad on vastavalt 52.7 ja 20.38. Koguvõlg on 48.75, netovõlg on 20.57. Muud lühiajalised kohustused moodustavad 24.52, mis lisandub kohustuste kogusummale 144.58. Lõpuks hinnatakse viidatud aktsia 0, kui see on olemas.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992

balance-sheet.row.cash-and-short-term-investments

85.3228.338.354.6
53.1
39.4
40.7
64.9
24.1
34.7
139.8
196.1
200.8
134.6
71.4
64.7
75
193.9
306.3
387.5
395.2
352.4
298.1
26.6
7.9
0.9
10.9
12.7
11
35.1
22
1.8

balance-sheet.row.short-term-investments

0.590.20.2-19.6
-20.5
1.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.2
0.2
1.4
6.6
10
1.4
0.1

balance-sheet.row.net-receivables

388.6124.3147.8162.9
146.3
142.5
153.6
160.3
264.6
161.5
171.6
269.9
364.5
183
156.4
159.5
364.7
357.3
393
389
179.8
144.7
224.3
37.3
11.8
1.8
16
11.6
2.6
5.9
3.5
10.4

balance-sheet.row.inventory

1653.02408.8430.7449.1
556.5
580.6
584.1
461.6
211.9
42.3
48.2
32.8
43.1
42
191.4
59.3
143
179.8
116.7
154
165
185.1
193.2
48.3
39.6
14.6
5.9
15.2
32.8
28.8
32.5
7

balance-sheet.row.other-current-assets

17.463.43.72.3
0
0.8
-8.7
-10.9
-57.8
110
90
-42.5
-102.5
-3.5
-9.8
132.4
-101.6
-65.5
-81.8
-85.8
-4.4
-8.2
-18.7
65.2
60.4
70.2
123
93.8
81.8
84.1
79.6
34.3

balance-sheet.row.total-current-assets

2144.24564.8620.4668.9
755.9
763.4
769.8
675.9
442.8
348.6
449.6
456.4
505.9
356
409.5
416
481
665.4
734.2
844.7
735.5
674
696.9
177.3
119.7
87.5
155.8
133.3
128.2
153.8
137.5
53.6

balance-sheet.row.property-plant-equipment-net

319.985.19284.5
80.9
89.5
79.9
241.8
304
330.2
237.3
250
247.1
251.3
266.6
269.3
317.4
420
432.9
340.3
321
294.9
231.6
74.1
71.8
65.8
72.6
105.3
73.5
90.9
83.1
59.6

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
6.3
6.3
0
0
0
12.3
48.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

153.6646.641.344
49.8
40
45.6
69.3
59.1
102
98
161.7
172.4
168.9
27.3
42.6
52.2
87.9
79.8
148.6
161.2
163
150.1
0
0
3.2
5.4
5.7
6.1
6.5
6.9
7.2

balance-sheet.row.goodwill-and-intangible-assets

153.6646.641.344
49.8
40
45.6
69.3
59.1
102
98
168
178.7
168.9
27.3
42.6
64.5
87.9
79.8
148.6
161.2
163
150.1
0
0
3.2
5.4
5.7
6.1
6.5
6.9
7.2

balance-sheet.row.long-term-investments

1.050.40.521
21.9
0
25.5
23.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
25.3
0
0
0
0
0
0

balance-sheet.row.tax-assets

17.665.24.55.3
7.2
6.3
4.4
4
4.5
12.4
12
11.8
10.8
1.6
3.7
0
0
0
0
0
0
0
0
0
0
-25.3
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

141.083640.50
0.2
26.7
6.4
3.1
24.1
24.9
25.7
26.6
27.5
184.2
45.5
48.2
20.4
55.2
48.6
55.7
12.4
13.1
3.3
23.3
25.2
23.8
65.4
29.6
53.6
32
27.2
6.7

balance-sheet.row.total-non-current-assets

633.36173.3178.9154.8
160
162.5
161.8
341.5
391.7
469.5
373
456.5
464.1
606
343.2
360.1
402.3
563.1
561.2
544.6
494.7
471
385
97.4
97
92.9
143.4
140.6
133.2
129.4
117.2
73.4

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

2777.6738.1799.3823.7
915.8
925.9
931.6
1017.4
834.5
818.1
822.6
912.9
969.9
962
752.7
776.1
883.3
1228.5
1295.5
1389.3
1230.2
1145
1081.9
274.7
216.7
180.3
299.2
273.9
261.4
283.2
254.6
127

balance-sheet.row.account-payables

230.7152.760.857.6
63.4
60.5
19.1
313.1
84.3
25.6
14.5
17.3
13.3
13.3
14.2
7.9
11.2
25.4
92.6
127.3
26.4
21.9
16
2.5
10
16.6
2.7
11.1
0
0.1
0
0

balance-sheet.row.short-term-debt

83.0920.420.316
16
70
50
53
35
1.7
9.6
0
0
0
1.8
51.8
2
132.1
141.7
92
52
3.4
3.4
25.9
24.3
18.8
30.9
33.7
21.2
18.4
18.3
17.5

balance-sheet.row.tax-payables

18.768.86.811.4
13.1
7.2
8.7
9.1
9
5.8
6.7
14.1
13.7
7.8
3.6
-2.8
1.6
6.4
-0.7
-3.7
10.2
8.1
14.7
4.8
2
2.3
0
1
-1.3
1.3
-0.3
0.1

balance-sheet.row.long-term-debt-total

111.7328.430.835.1
0
0
0
0
0
0
1.7
0
0
0
0
0
0
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
7.5
0.3
3.5
7.3
9.9
13.3
24.7

Deferred Revenue Non Current

000.81
0
0
1.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

79.4124.513.311.5
30.8
145
61.8
13.8
12.1
11.1
15.6
62
38.9
68.2
11.2
15.2
14.7
21.1
21
17.9
14.7
8.6
24.4
11.7
3.4
1.2
9.6
21.8
23.8
12.8
12
8.7

balance-sheet.row.total-non-current-liabilities

114.5128.431.61
1.7
0.4
2.2
1
16.6
4.9
6.5
3.3
1.9
0.8
0
2.6
1.7
0.3
0.2
0.2
0.2
0.2
0.2
0.2
0.2
7.6
0.5
3.7
7.4
9.9
13.6
33.1

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

111.7328.430.835.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

594.86144.6152.5138.7
255.5
283.1
256.1
406.3
225.8
96.5
91.8
82.6
54.2
82.3
40.3
83.2
49.5
217.4
292.6
282.4
134.5
82.4
98.9
69.8
59.9
76
109.3
93.4
52.4
54.6
43.9
59.4

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

4118.221029.61029.61029.6
1029.6
1029.6
1029.6
1029.6
1029.6
1029.6
1029.6
1029.6
1029.6
1029.6
1029.6
1029.6
1029.6
1029.6
1029.6
1029.6
1029.6
514.8
178.7
133.7
133.7
133.7
133.7
133.7
133.7
121.6
101.3
61.3

balance-sheet.row.retained-earnings

-2326.92-546.6-497.8-463
-490.3
-504.7
-475.2
-482.5
-487
-412.5
-418.5
-347.8
-357.9
-351.9
-355.9
-379.3
-239.4
-67.8
-76.9
26.6
17.1
115.9
56.5
9.8
-35.6
-96.9
-19.1
-24.9
5.1
22.9
17.4
0

balance-sheet.row.accumulated-other-comprehensive-income-loss

187.9638.738.738.7
38.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

71.1535.635.635.6
35.6
74.3
74.3
64.1
64.1
64.1
64.1
64.1
38.7
38.7
38.7
38.7
38.7
43.2
47.1
47.1
45.4
428.3
744.8
61.3
58.7
67.4
71.2
70.2
70.2
82.3
89.7
6.2

balance-sheet.row.total-stockholders-equity

2050.41557.2606640.8
613.5
599.2
628.6
611.1
606.6
681.1
675.1
745.8
710.4
716.4
712.4
689
828.9
1004.9
999.8
1103.3
1092.1
1059
980
204.8
156.8
104.3
185.8
179
209
226.8
208.4
67.6

balance-sheet.row.total-liabilities-and-stockholders-equity

2777.6738.1799.3823.7
915.8
925.9
931.6
1017.4
834.5
818.1
822.6
912.9
969.9
962
752.7
776.1
883.3
1228.5
1295.5
1389.3
1230.2
1145
1081.9
274.7
216.7
180.3
299.2
273.9
261.4
283.2
254.6
127

balance-sheet.row.minority-interest

132.3336.340.744.2
46.8
43.6
46.9
0
2.1
40.5
55.7
84.4
205.3
163.3
0
3.8
4.9
6.2
3.1
3.5
3.6
3.6
3
0
0
0
4.2
1.6
0
1.8
2.4
0

balance-sheet.row.total-equity

2182.74593.5646.8685
660.3
642.8
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

2777.6---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

1.640.50.71.3
1.4
1.4
25.5
23.2
0
0
0
0
0
150
0
1.4
6.5
7.5
14.8
17.7
12.4
13.1
3.1
17.6
20.2
25.5
0.2
1.4
6.6
10
1.4
0.1

balance-sheet.row.total-debt

194.8348.751.116
16
70
50
53
35
1.7
11.2
0
0
0
1.8
51.8
2
132.1
141.7
92
52
3.4
3.4
25.9
24.3
26.2
31.2
37.2
28.5
28.3
31.6
42.2

balance-sheet.row.net-debt

110.120.613-38.6
-37.1
30.6
9.3
-11.9
10.9
-33.1
-128.5
-196.1
-200.8
-134.6
-69.7
-12.9
-73
-61.8
-164.6
-295.5
-343.1
-349.1
-294.8
-0.6
16.4
25.5
20.5
25.9
24.1
3.2
11
40.5

Rahavoogude aruanne

Jiangsu Sihuan Bioengineering Co., Ltd finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab 0.521 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 0, mis tähistab 0.000 erinevust võrreldes eelmise aastaga. Huvitav on see, et osa ettevõtte aktsiatest, täpsemalt 0, ostis ettevõte ise tagasi. Selle tegevuse tulemusena muutus 0.000 võrreldes eelmise aastaga. Vahepeal on ettevõtte võlgnevused praegu 2.58 aruandlusvaluutas. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli -8474789.500. See on -0.077 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 24.75, 0, -16, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte -0.72 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui 10.14, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998

cash-flows.row.net-income

-59.28-53.3-38.327.7
17.5
-29.7
10.7
5.6
-112.9
-9.2
-99.5
14.5
2.5
5.7
23.3
-140.9
-178.2
6.6
-103.9
11.1
69
86.3
77.4
53
38.7
-31.2

cash-flows.row.depreciation-and-amortization

18.0824.82418.4
18.9
16.2
19
26.7
23.7
22.2
25.7
27
23.7
23.9
22.9
29.2
41
40.6
42.5
38.5
31.9
27
7.4
4.1
4.2
3.9

cash-flows.row.deferred-income-tax

0-0.70.81.9
-0.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

00.7-0.8-1.9
0.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

23.3317.92.259
9.8
20.3
-37.9
-45.2
-149.3
-32.8
-21.3
8.3
-14.9
173.1
16.5
93.2
63.2
-95.3
-8.3
-9.6
-20.8
55
-66.4
-36.2
-32.1
5.3

cash-flows.row.account-receivables

38.87-0.9-16-17.5
-51.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-15.54178.5109.7
24.1
0.3
3.2
-244.9
-181.9
5.8
-15.7
9.6
-1.1
2.1
8.8
62.7
13.6
-61.5
20.4
11
20.1
8.2
10.9
-8.6
-25.1
1.3

cash-flows.row.account-payables

02.69-35
37.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0-0.70.81.9
-1
20
-41.1
199.8
32.6
-38.6
-5.5
-1.2
-13.8
171
7.7
30.5
49.6
-33.9
-28.7
-20.5
-41
46.8
-77.3
-27.6
-7
4

cash-flows.row.other-non-cash-items

21.8615.512.2-4.8
12.4
15.8
-2.6
24.4
102.3
39.9
76
4.7
8.8
28.9
-5.7
87.3
101
10.8
64.3
14
2.9
3.6
11
2.7
-7.4
17.7

cash-flows.row.net-cash-provided-by-operating-activities

3.99000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-10.1-8.5-7.7-8.7
-15.2
-6.1
-24.1
-19.2
-30.3
-111
-15.8
-62.4
-39.7
-11.2
-6.1
-13.8
-18.8
-35.3
-117.2
-103.4
-54.4
-109.6
-95.5
-12.2
0
0

cash-flows.row.acquisitions-net

000.3-0.2
0.1
0
50.4
10.7
8.4
111.1
1.3
0
-27.2
-29.8
8.3
1.9
0
0
0
118.6
0
0
106
0
0
0

cash-flows.row.purchases-of-investments

-0.30-0.30
0
-24.5
24.4
0
-110
-110
-90
0
41.5
-150
-60
-130
-2.7
0
-6.4
-6.8
0
-10
-355.1
0
0
0

cash-flows.row.sales-maturities-of-investments

0000
0
23.3
2.3
0
222.9
97.3
4.7
3
111.4
15
200.6
4.6
0
0
41.9
1
0
0
0
2.8
4.7
0

cash-flows.row.other-investing-activites

-0.30-1.51
0
0
-24.1
17.8
5.6
-111
38.4
0.1
-39.7
20.8
0
10.2
10.1
6.7
-40
-103.4
0.2
6.5
-95.5
3.4
0
4.3

cash-flows.row.net-cash-used-for-investing-activites

-10.4-8.5-9.2-8
-15.1
-7.3
28.9
9.3
96.7
-123.7
-61.5
-59.3
46.2
-155.2
142.9
-127
-11.4
-28.6
-121.8
-94
-54.2
-113.1
-440.1
-6
4.7
4.2

cash-flows.row.debt-repayment

-16-16-16-16
-70
-50
-10
-35
-1.7
-9.6
-3.8
0
0
0
-227.4
0
-250
-239.6
-320
-320
-1.3
0
-86.8
0
-34.5
-11.3

cash-flows.row.common-stock-issued

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

-0.76-0.7-0.7-0.5
-3.5
-2.7
-11.8
-2
-1.9
-0.5
-0.9
0
0
0
-14.7
-1.9
-4.4
-3.6
-3.8
-7.7
-34.7
-4.5
-6.8
-0.1
-0.9
-1.8

cash-flows.row.other-financing-activites

10.6810.19-73.9
44
36
-20.5
61.2
35
1.6
28.7
0
0
0
49
50
150
266.6
279.8
360
50
0
775.8
1.2
34.4
11.3

cash-flows.row.net-cash-used-provided-by-financing-activities

-6.08-6.6-7.7-90.5
-29.5
-16.7
-42.3
24.2
31.5
-8.4
24
0
0
0
-193.2
48.1
-104.4
23.4
-44
32.3
14
-4.5
682.2
1.1
-1
-1.8

cash-flows.row.effect-of-forex-changes-on-cash

0.0500-0.3
-0.3
0.1
0
0
0
0.1
0.1
0
0
0
0
0
0
65.9
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

-12.44-10.2-16.71.5
13.7
-1.3
-24.2
45.1
-8
-111.9
-56.4
-4.7
66.2
63.2
6.7
-10.3
-88.9
23.4
-171.1
-7.7
42.8
54.3
271.5
18.7
7.2
-2

cash-flows.row.cash-at-end-of-period

69.527.737.954.6
53.1
39.4
40.7
64.9
19.9
27.8
139.8
196.1
200.8
134.6
71.4
64.7
75
23.4
206.3
387.5
395.2
352.4
298.1
26.6
7.9
0.7

cash-flows.row.cash-at-beginning-of-period

81.9437.954.653.1
39.4
40.7
64.9
19.9
27.8
139.8
196.1
200.8
134.6
71.4
64.7
75
163.9
0
377.4
395.2
352.4
298.1
26.6
7.9
0.7
2.7

cash-flows.row.operating-cash-flow

3.994.90.2100.2
58.6
22.6
-10.8
11.6
-136.1
20.1
-19
54.6
20.1
231.6
57
68.7
26.9
-37.3
-5.4
54.1
82.9
171.9
29.4
23.6
3.4
-4.4

cash-flows.row.capital-expenditure

-10.1-8.5-7.7-8.7
-15.2
-6.1
-24.1
-19.2
-30.3
-111
-15.8
-62.4
-39.7
-11.2
-6.1
-13.8
-18.8
-35.3
-117.2
-103.4
-54.4
-109.6
-95.5
-12.2
0
0

cash-flows.row.free-cash-flow

-6.1-3.6-7.591.5
43.4
16.5
-34.9
-7.6
-166.4
-91
-34.8
-7.8
-19.7
220.4
50.9
54.9
8.1
-72.6
-122.7
-49.4
28.5
62.3
-66.1
11.3
3.4
-4.4

Kasumiaruande rida

Jiangsu Sihuan Bioengineering Co., Ltd tulud muutusid võrreldes eelmise perioodiga -0.230%. 000518.SZ brutokasum on teatatud 191.9. Ettevõtte tegevuskulud on 230.9, mille muutus võrreldes eelmise aastaga on -13.465%. Kulud amortisatsioonikulud on 24.75, mis on 0.152% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 230.9, mis näitab -13.465% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab -0.681% kasvu võrreldes eelmise aastaga. Tegevustulu on -39, mis näitab 0.681% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on 0.392%. Eelmise aasta puhaskasum oli -53.28.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997199619951994199319921991

income-statement-row.row.total-revenue

234.8270.1351505.4
417.9
395.5
346.1
327.3
237.8
241.2
208.7
262.5
244.1
208.4
194.1
179.4
281.3
281.1
205.7
311.5
375.7
470.1
366.8
187.2
105.2
0.5
206.7
83.5
59.2
82
62.3
73.6
75.9

income-statement-row.row.cost-of-revenue

69.1678.2107.3212.9
106.9
98.4
82.8
113.2
90
98.2
103.8
134.2
126.6
110.6
111.5
179.6
236.2
201.6
171.2
221.7
243.2
330.3
239.6
120.7
73.7
0.7
186.5
94.5
60.8
73.4
53.8
0
0

income-statement-row.row.gross-profit

165.64191.9243.6292.5
311
297.1
263.2
214.1
147.8
143
104.9
128.3
117.5
97.8
82.6
-0.2
45.1
79.5
34.6
89.8
132.4
139.8
127.2
66.6
31.5
-0.2
20.3
-10.9
-1.6
8.6
8.6
73.6
75.9

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

28.71---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

70.15---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

98.58---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0.2936.436.244.1
42
-1.5
-1.7
14.7
14.5
0.2
-2.8
3.3
1.4
16.4
0.6
9.5
-63.1
1.3
-49.9
22.7
20.1
31
0.5
5.2
23.7
-5.7
-5.2
-1.5
2.2
1.2
-0.1
0
0

income-statement-row.row.operating-expenses

224.42230.9266.8257.5
270.8
314.4
250.5
192.5
142.3
104
121.7
107.3
102.3
80.8
66.3
63.9
79.3
66.3
103.8
88.7
57
58.4
30.4
15.1
14.1
16
20.5
15.6
10.1
6.8
4.8
0
0

income-statement-row.row.cost-and-expenses

293.58309.2374.2470.4
377.7
412.7
333.3
305.7
232.3
202.3
225.5
241.5
228.9
191.3
177.8
243.5
315.5
267.9
275
310.4
300.2
388.7
270
135.8
87.9
16.7
207
110.1
70.9
80.3
58.6
0
0

income-statement-row.row.interest-income

3.470.10.10.1
0.1
0.1
0.1
0.1
0.2
0.3
0.6
0.8
0.7
0.6
0.3
0.4
1.1
1.6
2.8
3
2.3
2.4
1.2
0.1
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

1.180.70.70.8
3.4
2.9
1.9
13.3
5.8
4.4
6.1
0
0
0
2.1
0.1
3.6
3.5
4.7
6.2
1.6
2
2.4
1.2
2.4
3.3
-0.3
2.2
-1.7
-4.5
-3.1
0
0

income-statement-row.row.selling-and-marketing-expenses

98.58---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-26.2-14.6-12.85.1
-12.4
-13.1
4.1
-8.9
-100.9
-38.5
-77.3
0.1
-10.5
-8.3
7.8
-76.8
-144
-2.8
-35.6
-4.6
-1.7
0.2
-1
0.8
10.2
-14.7
8.5
-2.9
-4.9
17.8
20.3
-66.1
-71.8

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0.2936.436.244.1
42
-1.5
-1.7
14.7
14.5
0.2
-2.8
3.3
1.4
16.4
0.6
9.5
-63.1
1.3
-49.9
22.7
20.1
31
0.5
5.2
23.7
-5.7
-5.2
-1.5
2.2
1.2
-0.1
0
0

income-statement-row.row.total-operating-expenses

-26.2-14.6-12.85.1
-12.4
-13.1
4.1
-8.9
-100.9
-38.5
-77.3
0.1
-10.5
-8.3
7.8
-76.8
-144
-2.8
-35.6
-4.6
-1.7
0.2
-1
0.8
10.2
-14.7
8.5
-2.9
-4.9
17.8
20.3
-66.1
-71.8

income-statement-row.row.interest-expense

1.180.70.70.8
3.4
2.9
1.9
13.3
5.8
4.4
6.1
0
0
0
2.1
0.1
3.6
3.5
4.7
6.2
1.6
2
2.4
1.2
2.4
3.3
-0.3
2.2
-1.7
-4.5
-3.1
0
0

income-statement-row.row.depreciation-and-amortization

16.5224.22118.4
18.9
16.2
19
26.7
23.7
22.2
25.7
27
23.7
23.9
22.9
29.2
41
40.6
42.5
38.5
31.9
27
7.4
4.1
4.2
3.9
-14.2
1.2
2.5
-17.6
-20.3
0
0

income-statement-row.row.ebitda-caps

-18.87---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-35.39-39-23.231.3
40.2
-28.8
18.5
-1
-108.7
1.3
-91.3
17.8
3.3
6.4
23.5
-150.4
-115.1
11.5
-53.1
20.2
96.9
113.2
95.8
56.1
26.1
-25.9
13.9
-27.8
-14.2
19.3
24.1
73.6
75.9

income-statement-row.row.income-before-tax

-61.59-53.6-3636.4
27.8
-30.3
16.8
12.8
-95.3
0.4
-94.1
21.1
4.7
8.8
24.1
-140.9
-178.2
11.5
-103.9
19.7
95.4
113.1
96
56.8
38.7
-31.2
8.5
-29.4
-14.3
20
24
7.6
4.2

income-statement-row.row.income-tax-expense

2.58-0.32.28.8
10.4
-0.6
6.2
7.2
17.6
9.6
5.4
6.6
2.2
-0.5
0.7
13.9
-67.4
4.9
-31.3
8.6
26.4
26.9
18.6
3.8
-11.1
0.3
2.7
-2
-4.8
2
3.6
1.1
0.3

income-statement-row.row.net-income

-59.28-53.3-38.327.3
14.3
-29.4
7.3
4.5
-74.4
6
-70.7
10.1
-6
7.7
23.3
-139.9
-176.8
7.2
-103.5
11.2
69
85.7
76.4
53
38.7
-31.2
5.8
-28.6
-14.3
18.4
20.4
6.4
3.8
Sarnased aktsiad
Sind võib huvitada ka:
SRNE
Sorrento Therapeutics, Inc..
0.014 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
8.8 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.03 USD
NASDAQ
GUBRA.CO
Gubra A/S.
296 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.04 NOK
OSL
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.05 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

Korduma kippuv küsimus

Mis on Jiangsu Sihuan Bioengineering Co., Ltd (000518.SZ) koguvara?

Jiangsu Sihuan Bioengineering Co., Ltd (000518.SZ) koguvara on 738078462.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on 111882288.000.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.705.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on -0.006.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on -0.252.

Mis on ettevõtte kogutulu?

Kogutulu on -0.151.

Mis on Jiangsu Sihuan Bioengineering Co., Ltd (000518.SZ) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on -53281016.880.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 48749843.000.

Mis on tegevuskulude arv?

Tegevuskulud on 230901302.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 16499358.000.